Healionics
Healionics is a Seattle-based biomaterials company focused on improving bloodstream access for dialysis patients, operating in the...
Facts
- HQ
- Seattle, Washington
- Sectors
- Medical Device
- Founded
- 2007
- Type
- Corporation Seattle business license
- Employees
- 9
- Registered name
- Healionics Corp Seattle business license
- Total raised
- $18.2M SEC Form D filings Total of this company's SEC Form D filings
- Last round
- $2M · Dec 2025 SEC Form D
Healionics Raises $5.5M to Complete Human Trial of STARgraft Artificial Blood Vessel for Dialysis Patients
Healionics, a Seattle-based medical tech company, raised $5.5 million to complete human trials and pursue regulatory approval for its STARgraft artificial blood vessel designed for dialysis patients. The STARgraft aims to provide a durable vascular access solution resistant to blockages and infections that commonly affect dialysis patients.
Healionics raises $4.7M led by Keiretsu Capital to commercialize STARgraft artificial blood vessel, aims for early‑next‑year launch
Seattle medical device company Healionics raised $4.7 million led by Keiretsu Capital to commercialize STARgraft, a synthetic vascular graft designed to resist occlusion for dialysis patients, and plans a commercial launch early next year. The funding will finance a second human study and FDA clearance efforts; the company also converted $5.2 million of notes and interest into equity.
